{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05345769",
            "orgStudyIdInfo": {
                "id": "AM712E1001"
            },
            "organization": {
                "fullName": "AffaMed Therapeutics Limited",
                "class": "INDUSTRY"
            },
            "briefTitle": "Safety and Efficacy of AM712 in Patients With nAMD",
            "officialTitle": "A Prospective, Multi-Center, Open-label, Sequential, Multiple Ascending-Dose and High Concentration Cohorts Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AM712 Following Intravitreal Administration in Patients With Neovascular Age-related Macular Degeneration.",
            "therapeuticArea": [
                "Ophthalmology"
            ],
            "study": "safety-and-efficacy-of-in-patients-with-namd"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-04-28",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-06-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-06-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-04-12",
            "studyFirstSubmitQcDate": "2022-04-21",
            "studyFirstPostDateStruct": {
                "date": "2022-04-26",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-07-24",
            "lastUpdatePostDateStruct": {
                "date": "2023-07-25",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "AffaMed Therapeutics (US) Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this Phase 1 study is comprised of multiple ascending-dose component (Part 1) and high concentration component (Part 2) to evaluate the safety, tolerability, pharmacokinetics, and efficacy of AM712 in patients with neovascular age- related macular degeneration (nAMD).",
            "detailedDescription": "The Part 1 of study is a multicenter, open-label, sequentially, multiple ascending-dose study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of AM712 in subjects with nAMD.\n\nSubjects will be sequentially enrolled into different dose-level cohorts following the traditional \"3+3\" design until the maximally tolerated dose (MTD) or the maximally administered dose (MAD) has been reached.\n\nThe Part 2 of study is a multicenter, open-label, sequential study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of AM712 in treatment-na\u00efve patients with nAMD."
        },
        "conditionsModule": {
            "conditions": [
                "Neovascular Age-related Macular Degeneration"
            ],
            "keywords": [
                "nAMD"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE",
                    "maskingDescription": "The Phase 1 study is comprised of open-label multiple ascending-dose component (Part 1) and high concentration component (Part 2) to evaluate the safety, tolerability, pharmacokinetics, and efficacy of AM712 in patients with neovascular age- related macular degeneration (nAMD)."
                }
            },
            "enrollmentInfo": {
                "count": 24,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Phase I- All",
                    "type": "EXPERIMENTAL",
                    "description": "Subjects with neovascular AMD",
                    "interventionNames": [
                        "Biological: AM712(ASKG712)"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "AM712(ASKG712)",
                    "description": "AM712 is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein, which has high specificity for the binding of VEGF-A and Ang-2.",
                    "armGroupLabels": [
                        "Phase I- All"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence of ocular adverse events (AEs) of the study eyes",
                    "description": "To evaluate the safety and tolerability of AM712 in Subjects with neovascular Age-related Macular Degeneration (nAMD)",
                    "timeFrame": "252 days"
                },
                {
                    "measure": "Incidence of non-ocular AEs",
                    "description": "To evaluate the safety and tolerability of AM712 in Subjects with neovascular Age-related Macular Degeneration (nAMD)",
                    "timeFrame": "252 days"
                },
                {
                    "measure": "Any relevant safety observations derived from BCVA",
                    "description": "To evaluate the safety and tolerability of AM712 in Subjects with neovascular Age-related Macular Degeneration (nAMD)",
                    "timeFrame": "252 days"
                },
                {
                    "measure": "Any relevant safety observations derived from SD-OCT",
                    "description": "To evaluate the safety and tolerability of AM712 in Subjects with neovascular Age-related Macular Degeneration (nAMD)",
                    "timeFrame": "252 days"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Mean change from baseline in central subfield thickness as assessed by SD-OCT",
                    "description": "To evaluate the efficacy of AM712 in Subjects with nAMD",
                    "timeFrame": "252 days"
                },
                {
                    "measure": "Proportion of patients with no intraretinal fluid, subretinal fluid, or pigment epithelial detachment as assessed by SD-OCT",
                    "description": "To evaluate the efficacy of AM712 in Subjects with nAMD",
                    "timeFrame": "252 days"
                },
                {
                    "measure": "Mean change from baseline in BCVA (ETDRS)",
                    "description": "To evaluate the efficacy of AM712 in Subjects with nAMD",
                    "timeFrame": "252 days"
                },
                {
                    "measure": "Proportion of patients gaining \u2265 15 letters from baseline BCVA",
                    "description": "To evaluate the efficacy of AM712 in Subjects with nAMD",
                    "timeFrame": "252 days"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Male or female subjects with 50 years of age or older\n2. Active sub-foveal CNV lesion secondary to nAMD including juxta or extra-foveal lesions that partially affect the fovea\n3. The area of CNV must occupy at least 50% of total lesion\n4. Total lesion area \u2264 12 DA\n5. ETDRS BCVA letter score measured at screening and baseline\n6. Clear ocular media and adequate pupil dilation to permit good quality photographic imaging in study eye\n\nExclusion Criteria:\n\n1. Any previous systemic anti-VEGF treatment\n2. Any systemic treatment or therapy to treat neovascular AMD\n3. Continuous use of systemic corticosteroids\n4. Diseases that affect intravenous injection and venous blood sampling\n5. Presence of CNV due to other causes, such as ocular histoplasmosis, trauma, multifocal choroiditis, angioid streaks, history of choroidal rupture, or pathologic myopia in study eye\n6. History or any concurrent ocular condition which, in opinion of investigator, could either confound interpretation of efficacy and safety of IP or require medical or surgical intervention.\n7. The area of fibrosis occupies \u2265 50% of total lesion area in study eye\n8. Evidence of myopia degeneration, diagnosis supported by the axial length examination in study eye\n9. History or any concurrent macular abnormality other than AMD in study eye\n10. Current vitreous hemorrhage or history of vitreous hemorrhage in study eye\n11. History of recurrent inflammation in study eye\n12. History of treatment for nAMD\n13. Subject having out of range laboratory values defined as:\n\nALT or AST \\> 2 x ULN, total bilirubin \\> 1.5 x ULN Serum creatinine \\> 1.5 x ULN, BUN \\> 2 x ULN HbA1c \\> 7.5% at screening",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "50 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Fan Yang",
                    "role": "CONTACT",
                    "phone": "+1 (306) 580-5857",
                    "email": "fan.yang@affamed.com"
                }
            ],
            "locations": [
                {
                    "facility": "Retina Consultants San Diego",
                    "status": "RECRUITING",
                    "city": "Poway",
                    "state": "California",
                    "zip": "92064",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Nikolas London",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.96282,
                        "lon": -117.03586
                    }
                },
                {
                    "facility": "Bay Area Retina Associates",
                    "status": "RECRUITING",
                    "city": "Walnut Creek",
                    "state": "California",
                    "zip": "94598",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Roger Goldberg",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.90631,
                        "lon": -122.06496
                    }
                },
                {
                    "facility": "Colorado Retina",
                    "status": "SUSPENDED",
                    "city": "Lakewood",
                    "state": "Colorado",
                    "zip": "80228",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.70471,
                        "lon": -105.08137
                    }
                },
                {
                    "facility": "Florida Eye Associates",
                    "status": "RECRUITING",
                    "city": "Melbourne",
                    "state": "Florida",
                    "zip": "32901",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Vrinda Hershberger",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 28.08363,
                        "lon": -80.60811
                    }
                },
                {
                    "facility": "Retina Research Institute at New England Retina Consultants",
                    "status": "RECRUITING",
                    "city": "Springfield",
                    "state": "Massachusetts",
                    "zip": "01107",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "David Lally",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.10148,
                        "lon": -72.58981
                    }
                },
                {
                    "facility": "Tennessee Retina, PC",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Eric W. Schneider",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "Retina Consultants of Texas",
                    "status": "RECRUITING",
                    "city": "Bellaire",
                    "state": "Texas",
                    "zip": "77401",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "David M. Brown",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.70579,
                        "lon": -95.45883
                    }
                },
                {
                    "facility": "Retina Consultants of Texas",
                    "status": "RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78240",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Gary Lane",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                },
                {
                    "facility": "Retina Consultants of Texas",
                    "status": "RECRUITING",
                    "city": "The Woodlands",
                    "state": "Texas",
                    "zip": "77384",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Charles C. Wykoff",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 30.15799,
                        "lon": -95.48938
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008268",
                    "term": "Macular Degeneration"
                },
                {
                    "id": "D000057135",
                    "term": "Wet Macular Degeneration"
                }
            ],
            "ancestors": [
                {
                    "id": "D000012162",
                    "term": "Retinal Degeneration"
                },
                {
                    "id": "D000012164",
                    "term": "Retinal Diseases"
                },
                {
                    "id": "D000005128",
                    "term": "Eye Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11260",
                    "name": "Macular Degeneration",
                    "asFound": "Age-related Macular Degeneration",
                    "relevance": "HIGH"
                },
                {
                    "id": "M28735",
                    "name": "Wet Macular Degeneration",
                    "asFound": "Neovascular Age-related Macular Degeneration",
                    "relevance": "HIGH"
                },
                {
                    "id": "M14997",
                    "name": "Retinal Degeneration",
                    "relevance": "LOW"
                },
                {
                    "id": "M14999",
                    "name": "Retinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8271",
                    "name": "Eye Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC11",
                    "name": "Eye Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                },
                {
                    "id": "M4230",
                    "name": "Antibodies, Monoclonal",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}